Why do cancer drugs get such an easy ride?: Rushed approvals result in a poor deal for both patients and cancer research

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Light, Donald W ^a   Lexchin, Joel ^b  

^a UMDNJ School of Osteopathic Medicine   (United States)

^b YORK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB;

BREAST METASTASIS; CANCER RESEARCH; CANCER SURVIVAL; DRUG APPROVAL; DRUG EFFICACY; DRUG QUALITY; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SOLID TUMOR; SURVIVAL TIME; TUMOR VOLUME; DRUG INDUSTRY; HEALTH CARE QUALITY; PHASE 3 CLINICAL TRIAL (TOPIC); TOTAL QUALITY MANAGEMENT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; QUALITY ASSURANCE, HEALTH CARE; QUALITY IMPROVEMENT;

EID: 84930661581     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h2068     Document Type: Editorial

References (21)

1. Sontag S. Illness as metaphor . Farrar, Straus, and Giroux, 1978.
2. Herper M. The FDA's cancer czar says he can't approve new drugs fast enough. Forbes 2013 Jun 23. www.forbes.com/sites/matthewherper/2013/06/23/the-fdas-cancer-czarsays- he-cant-approve-new-drugs-fast-enough/.
3. Hirsch B, Califf R, Cheng S, et al. Characteristics of oncology clinical trials: insights from a systematic analysis of Clinicaltrials.gov. JAMA Intern Med 2013;173:972-9.
4. Apolone G, Joppi R, Bertele V, et al. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. Br J Cancer 2005;93:504-9.
5. Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics - the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity. The John Conley lecture. JAMA Otolaryngol Head Neck Surg 2014;140:1225-36.
6. Ellis L, Bernstein D, Voest E, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 2014;32:1277-80.
7. Darrow J, Avorn J, Kesselheim A. New FDA breakthrough-drug category - implications for patients. N Engl J Med 2014;370:1252-8.
8. Arnardottir A, Hasijer-Ruskamp F, Straus S, et al. Additional safety risk to exceptionally approved drugs in Europe. Br J Clin Pharmacol 2011;72:490-9.
9. Berlin R. Examination of the relationship between oncology drug labeling revision frequency and FDA product categorization. Am J Pub Health 2008;99:1693-8.
10. Effects of cancer drugs on survival: often poorly evaluated. Prescrire Int 2009;18:180-3.
11. Cheema P, Burkes R. Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer. Curr Oncol 2013;20:e150-60.
12. Han K, Ren M, Wick W, et al. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro-oncol 2014;16:696-706.
13. Venook A, Tabernero J. Progression-free survival: helpful biomarker or clinically meaningless end point? J Clin Oncol 2015;33:4-6.
14. Institute for Quality and Efficiency in Healthcare. Validity of surrogate endpoints in oncology: executive summary. 2011. www.ncbi.nlm.nih.gov/pubmedhealth/PMH0065194.
15. Johnson J, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003;21:1404-11.
16. Light D, Kantarjian H. Market spiral pricing of cancer drugs. Cancer 2013;119:3900-2.
17. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-42.
18. Belleli R, Fisch R, Szucs T. Regulatory watch: efficiency indicators for new drugs approved by the FDA from 2003 to 2013. Nat Rev Drug Discovery 2015;14:156.
19. Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ 2012;345:e4348.
20. Light D, Lexchin J, Darrow J. Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. J Law Med Ethics 2013;41:590-600.
21. Light D, Maturo A. Good pharma: the public-health model of the Mario Negri Institute . Palgrave, Macmillan, 2015.